Your browser doesn't support javascript.
Pathomechanisms, therapeutic targets and potent inhibitors of some beta-coronaviruses from bench-to-bedside.
Ayipo, Yusuf Oloruntoyin; Yahaya, Sani Najib; Alananzeh, Waleed A; Babamale, Halimah Funmilayo; Mordi, Mohd Nizam.
  • Ayipo YO; Centre for Drug Research, Universiti Sains Malaysia, USM, 11800 Pulau Pinang, Malaysia; Department of Chemistry, Kwara State University, P. M. B. 1530, Malete, Ilorin, Nigeria.
  • Yahaya SN; Centre for Drug Research, Universiti Sains Malaysia, USM, 11800 Pulau Pinang, Malaysia.
  • Alananzeh WA; Centre for Drug Research, Universiti Sains Malaysia, USM, 11800 Pulau Pinang, Malaysia.
  • Babamale HF; School of Chemistry, Universiti Sains Malaysia, USM, 11800 Pulau Pinang, Malaysia.
  • Mordi MN; Centre for Drug Research, Universiti Sains Malaysia, USM, 11800 Pulau Pinang, Malaysia. Electronic address: mnizam@usm.my.
Infect Genet Evol ; 93: 104944, 2021 09.
Article in English | MEDLINE | ID: covidwho-1246087
ABSTRACT
Since the emergence of their primitive strains, the complexity surrounding their pathogenesis, constant genetic mutation and translation are contributing factors to the scarcity of a successful vaccine for coronaviruses till moment. Although, the recent announcement of vaccine breakthrough for COVID-19 renews the hope, however, there remains a major challenge of accessibility to urgently match the rapid global therapeutic demand for curtailing the pandemic, thereby creating an impetus for further search. The reassessment of results from a stream of experiments is of enormous importance in identifying bona fide lead-like candidates to fulfil this quest. This review comprehensively highlights the common pathomechanisms and pharmacological targets of HCoV-OC43, SARS-CoV-1, MERS-CoV and SARS-CoV-2, and potent therapeutic potentials from basic and clinical experimental investigations. The implicated targets for the prevention and treatment include the viral proteases (Mpro, PLpro, 3CLpro), viral structural proteins (S- and N-proteins), non-structural proteins (nsp 3, 8, 10, 14, 16), accessory protein (ns12.9), viroporins (3a, E, 8a), enzymes (RdRp, TMPRSS2, ADP-ribosyltransferase, MTase, 2'-O-MTase, TATase, furin, cathepsin, deamidated human triosephosphate isomerase), kinases (MAPK, ERK, PI3K, mTOR, AKT, Abl2), interleukin-6 receptor (IL-6R) and the human host receptor, ACE2. Notably among the 109 overviewed inhibitors include quercetin, eriodictyol, baicalin, luteolin, melatonin, resveratrol and berberine from natural products, GC373, NP164 and HR2P-M2 from peptides, 5F9, m336 and MERS-GD27 from specific human antibodies, imatinib, remdesivir, ivermectin, chloroquine, hydroxychloroquine, nafamostat, interferon-ß and HCQ from repurposing libraries, some iron chelators and traditional medicines. This review represents a model for further translational studies for effective anti-CoV therapeutic designs.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Coronavirus Infections / Coronavirus / Host-Pathogen Interactions Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Infect Genet Evol Journal subject: Biology / Communicable Diseases / Genetics Year: 2021 Document Type: Article Affiliation country: J.meegid.2021.104944

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Coronavirus Infections / Coronavirus / Host-Pathogen Interactions Type of study: Prognostic study / Randomized controlled trials Topics: Vaccines Limits: Humans Language: English Journal: Infect Genet Evol Journal subject: Biology / Communicable Diseases / Genetics Year: 2021 Document Type: Article Affiliation country: J.meegid.2021.104944